«AVIVAC-IBD» strain Winterfield 2512

About the product

«AVIVAC-IBD» is a live dry vaccine against infectious bursal disease based on virus strain Winterfield 2512.

The vaccine is prepared from extraembryonic fluid, homogenized carcasses and chorioallantoic membranes of SPF chicken embryos infected with highly attenuated infectious bursal disease virus strain Winterfield 2512. The vaccine has the appearance of a homogenous dry brown porous substance that easily dissolves in water without forming flakes or sediment. The vaccine is available in hermetically sealed vials containing 100 to 5000 doses of the product.

Biological properties

One immunizing dose of the vaccine contains 3,0 lg EID₅₀/cm³ infectious bursal disease virus. Immunity in vaccinated chickens forms over a period of 2 to 3 weeks after vaccination and lasts throughout the entire period during which the birds are susceptible.
The vaccine is innocuous and non-reactogenic; it possesses no therapeutic properties.

Indications for use

Only clinically healthy birds are subject to vaccination. Chickens aged 7–21 days are vaccinated via drinking water. Time of vaccination is chosen on the basis of maternal antibody levels in the birds’ blood serum.

The robustness of post-vaccination immunity to IBD is evaluated 21 days after vaccination by way of performing serological testing (virus neutralization assay, gel diffusion precipitation test, ELISA) using diagnostic kits licensed for use in Russian Federation.

Vaccination is considered successful if not less than 80% of the immunized chickens demonstrate mean antibody titres against infectious bursal disease virus exceeding the minimum threshold value specified by the manufacturer of the kit by 100% or more.

If antibody titres fall below this level, re-vaccination must be conducted.

Storage requirements

The shelf life of the vaccine is 12 months from the date of manufacture if stored and transported in a dark dry place at a temperature between +2 and +10°С.